PLYMOUTH, Minn., Feb. 3, 2015 (GLOBE NEWSWIRE) — Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, announced today the closing of its initial public offering of 5,294,117 shares of its common stock (including 690,537 shares purchased by the underwriters pursuant to an option to purchase additional shares) at a public offering price of $17.00 per share, resulting in gross proceeds of approximately $90.0 million before underwriting discounts and commissions. The shares began trading on The NASDAQ Global Market under the ticker symbol “ENTL” on January 29, 2015.
BofA Merrill Lynch and Piper Jaffray acted as joint book-running managers for the offering. William Blair and Canaccord Genuity acted as co-managers.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and was declared effective by the SEC on January 28, 2015. The offering was made only by means of a written prospectus forming part of the effective registration statement. Copies of the prospectus relating to and describing the offering may be obtained by contacting BofA Merrill Lynch at 222 Broadway, New York, NY 10038, Attention: Prospectus Department or by e-mail at email@example.com or Piper Jaffray at 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Equity Capital Markets, by telephone at 800-747-3924 or by e-mail at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
CONTACT: Leigh Salvo
Entellus Medical, Inc.